Metastatic Melanoma
358
43
84
143
Key Insights
Highlights
Success Rate
64% trial completion
Published Results
112 trials with published results (31%)
Research Maturity
143 completed trials (40% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
22.3%
80 terminated out of 358 trials
64.1%
-22.4% vs benchmark
5%
18 trials in Phase 3/4
78%
112 of 143 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 143 completed trials
Clinical Trials (358)
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease